FDA Approved Indications for this Orphan Drug:Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
FDA Marketing Approval issued as of:
Amedra Pharmaceuticals LLC
FDA Designation Date:
FDA Drug Designation:
Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).